# A Study of Nemtabrutinib Plus Venetoclax vs Venetoclax + Rituximab (VR) in Second-line (2L) + Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) (MK-1026-010/BELLWAVE-010).

Source: https://onco.cc/trials/nct05947851/  
OnCo record `nct05947851` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial of Nemtabrutinib, Venetoclax and Rituximab in chronic lymphocytic leukaemia and non-Hodgkin lymphoma, run by Merck Sharp & Dohme LLC, now recruiting.

## Summary

A Study of Nemtabrutinib Plus Venetoclax vs Venetoclax + Rituximab (VR) in Second-line (2L) + Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) (MK-1026-010/BELLWAVE-010). is a phase 3 interventional study registered as NCT05947851 by Merck Sharp & Dohme LLC, with 735 participants planned, started 2023-08-08 and due to reach its primary completion in 2032-06-01. Interventions recorded: Nemtabrutinib, Venetoclax and Rituximab.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT05947851
- Phase: 3
- Setting: A Phase 3, Open-label, Randomized Study to Compare the Efficacy and Safety of Nemtabrutinib (MK-1026) Plus Venetoclax Versus Venetoclax Plus Rituximab in Participants With Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Following at Least 1 Prior Therapy (BELLWAVE-010)
- Sponsor: Merck Sharp & Dohme LLC
- Enrolled: 735

## Sources

- ClinicalTrials.gov NCT05947851: https://clinicaltrials.gov/study/NCT05947851

## Connected records

- cancers: [Chronic lymphocytic leukaemia](https://onco.cc/cancers/cll/), [Non-Hodgkin lymphoma (all types)](https://onco.cc/cancers/non-hodgkin-lymphoma/)
- drugs: [Nemtabrutinib](https://onco.cc/drugs/nemtabrutinib/), [Rituximab](https://onco.cc/drugs/rituximab/), [Venetoclax](https://onco.cc/drugs/venetoclax/)
- companies: [Merck & Co. (MSD)](https://onco.cc/companies/merck/)

---
JSON: https://onco.cc/api/v1/entities/nct05947851.json